What the FDA labels say about taking them together
Ozanimod and quinidine
Ozanimod's FDA label of April 16, 2026 names quinidine in its drug interactions section; the quinidine label PlainMeds reads does not name ozanimod. The ozanimod label: “ZEPOSIA has not been studied in patients taking QT prolonging drugs. Class Ia and Class III anti-arrhythmic drugs have been associated with cases of Torsades de Pointes in patients with bradycardia.”
Check it at the source: the ozanimod FDA label on DailyMed (effective April 16, 2026, Celgene Corporation); the quinidine FDA label on DailyMed (effective February 1, 2018, Sun Pharmaceutical Industries, Inc.).
What does the ozanimod label say about quinidine?
Ozanimod label, drug interactionsClinical Impact: ZEPOSIA has not been studied in patients taking QT prolonging drugs. Class Ia (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) anti-arrhythmic drugs have been associated with cases of Torsades de Pointes in patients with bradycardia. Prevention or Management: If treatment with ZEPOSIA is considered in patients on Class Ia or Class III anti-arrhythmic drugs, advice from a cardiologist should be sought [see Warnings and Precautions (5.3) ]. …
Source: FDA drug label (ZEPOSIA 7-Day Starter Pack), NDA209899 (Bristol), as published by Celgene Corporation, effective April 16, 2026 (SPL set 93ce2fab-edfb-4804-8074-963071de51e4), via openFDA; the full label on DailyMed
What does the quinidine label say about ozanimod?
Quinidine's label (effective February 1, 2018) does not name ozanimod in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Quinidine Gluconate), Sun Pharmaceutical Industries, Inc., effective February 1, 2018 (SPL set 5023f053-fcc4-4c2c-aa59-9ec198ad185e), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ozanimod | Quinidine | |
|---|---|---|
| Labeled for | n/a | Atrial fibrillation |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $4.92 per tablet 324 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once